{ "docId": "019dd923-5ca1-7489-b639-45501f4b359b", "docSlug": "158df8627a0b9aca", "documentTitle": "Opioid Conflicts Majority Staff Report", "authorId": "McKinsey", "authorName": "U.S. House Committee on Oversight and Reform", "documentKindSlug": "consulting-deck", "documentKindLabel": "Consulting deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "portrait", "aspectRatio": 0.773, "pageNumber": 29, "pageCount": 53, "prevPage": 28, "nextPage": 30, "slideType": "appendix_disclosure", "function": "other", "density": "overcrowded", "nDataPoints": 0, "notes": "This appears to be a page from a formal investigative report or committee document, given the footnote citations.", "elementsJson": [ "paragraph", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/29", "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b", "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json", "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-29", "components": [ { "bbox": null, "kind": "callout", "text": "The Committee has uncovered several instances in which McKinsey consultants appear to have received information from FDA related to the agency’s regulation of opioids, which the consultants then shared with McKinsey colleagues working for private sector opioid clients.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd951-cdec-74db-b49c-855eab7832b4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.81 }, "kind": "disclaimer", "text": "141 MCK-HCOR-0141703. 142 MCK-HCOR-0035338, Slide 11. 143 As discussed above, McKinsey consultants circulated material that appeared to have been drawn from the FDA Sentinel Initiative with colleagues working for Purdue. MCK-HCOR-0330664. 144 MCK-HCOR-0341883 (emphasis added). 145 Id.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f5e49275-0170-4b4b-8eda-04d556b8d697", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.15, "y": 0.65 }, "kind": "paragraph", "text": "On the same day, Rachel Sherman, then-Principal Deputy Director of FDA, sent a second document to FDA officials, including then-CDER Director Janet Woodcock, with notes about Commissioner Gottlieb’s input on the proposal document: “Scott will up the estimates from 500M to 650M. He would like a second version that gets us to 1B by COB tomorrow (in other words to expand the list).”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "5bc03766-6be6-4742-802d-5d31133c1fc1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.54 }, "kind": "paragraph", "text": "On January 23, 2018, an FDA official emailed then-FDA Commissioner Gottlieb and other senior officials a document entitled “Proposals for Consideration.” It is not clear what the proposals were, but later correspondence suggests that they involved spending priorities related to opioids and may have included federal initiatives connected to prescribing behavior that could have impacted McKinsey’s opioid clients.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6b769c7e-050a-468c-85b6-e002d79d738a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.15, "y": 0.38 }, "kind": "paragraph", "text": "The Committee has uncovered several instances in which McKinsey consultants appear to have received information from FDA related to the agency’s regulation of opioids, which the consultants then shared with McKinsey colleagues working for private sector opioid clients.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b95e35e7-d08c-446a-b579-c787a55f085f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.7, "x": 0.15, "y": 0.47 }, "kind": "paragraph", "text": "In one instance, a McKinsey consultant shared an FDA document concerning the opioid epidemic with another McKinsey consultant who at the time was working on a Purdue contract, though the precise nature of the document is not clear.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e97a7539-fed9-4553-b186-fb46cad7c9a4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.15, "y": 0.74 }, "kind": "paragraph", "text": "After sending this email, Ms. Sherman sent the document to McKinsey Senior Partner Navjot Singh, writing: “Doc 2. Thanks! PS Please keep this to you (feel free to include Jeff,", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "eedf4524-410f-4f43-bd01-34060d2c9b7d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.31 }, "kind": "title", "text": "4. McKinsey Consultants Shared FDA Information with Other Consultants Working for Private Sector Clients", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7516a2ba-9c0a-4e5e-bcfc-c61ff4ae9581", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 53, "from": 29, "beatId": "1170eac2-9202-4b41-a53c-edbd934ded10", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document concludes with implications of McKinsey's actions and potential next steps for regulatory action.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "loops": [ { "to": 53, "from": 1, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033", "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.", "position": 0, "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 40, "from": 24, "name": "Voice Of Customer", "slug": "51-voice-of-customer", "bestFor": "Product strategy, customer experience, market research", "matchId": "308c22ef-34f3-45b8-b50d-c273c6edeb88", "evidence": "The document presents the concerns of regulatory bodies through examples of McKinsey's actions and lack of disclosure.", "position": 1, "objective": "What are the concerns of regulatory bodies regarding McKinsey's conflicts of interest?", "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response", "confidence": 0.6, "description": "Let customer quotes and feedback drive the narrative and validate the insight" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }